| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 12 Feb 2025 | 30 Jan 2025 |
| NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025 inter alia to consider and approve the unaudited financial results for the quarter and nine months ended 31st December 2024 and 3rd Interim Dividend if any Unaudited Financial Results for the quarter and nine months ended December 31, 2024 (As Per Bse Announcement Dated on 12.02.2025) | ||
| Board Meeting | 12 Nov 2024 | 28 Oct 2024 |
| Quarterly Results & Interim Dividend Outcome of Board Meeting Declared second interim dividend of Rs.1.50 (Rupees one and fifty paise only) (75%) each per equity share of Rs.2/- (Rupees two only) each for the financial year 2024-25. The date for taking on record of its shareholders eligible for the purpose of payment ofsecond interim dividend i.e., record date is fixed as Monday, the 25th day of November 2024. The payment of said interim dividend will start from 2nd December 2024. (As Per BSE Announcement Dated on 12.11.2024) | ||
| Board Meeting | 12 Aug 2024 | 26 Jul 2024 |
| NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve the Un-audited Financial Results for the quarter ended June 30 2024 and declaration of Interim Dividend for FY 2024-25 if any Unaudited Financial Results for the quarter ended 30th June 2024 along with Limited Review Report (As Per BSE Announcement Dated on 12.08.2024) | ||
| Board Meeting | 27 May 2024 | 9 May 2024 |
| NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2024 inter alia to consider and approve the Audited Financial Results for the quarter and year ended March 31 2024 Audited Financial Results for the quarter and year ended 31st March, 2024 (As Per BSE Announcement Dated on 27.05.2024) | ||
The drug enhances the flow of blood through the lungs, allowing children with PAH to breathe and improve their ability to engage in physical activity.
The company was ensured that the sale of the land and building did not constitute part of its operational assets so that the sale will, in no way, impact the company's business operations
The revenue for the September quarter rose by 33% to ₹1,371 crore from ₹1,031 crore in the corresponding period last year.
According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.
The plan to reduce the GST on these drugs aims to significantly reduce the overall cost of cancer treatment.
Natco Pharma disclosed that its subsidiary will invest USD 8 million in eGenesis, acquiring a total of 40,629,761 shares.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
